Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-10-12
Based on 1255 first isolates · PHC-S · Cystitis (lower UTI) · 2024-10-13 → 2025-10-12
Health centre South
Per-organism detail: PHC-S urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (80 %–84 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
90 %
n = 105
meropenem MEM
trend · Escherichia coli reserve
82 %
85 %
n = 105
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
82 %
n = 105
ciprofloxacin CIP
trend · Escherichia coli
76 %
75 %
n = 105
mecillinam MEC
trend · Escherichia coli lower UTI only
75 %
82 %
n = 105
ceftriaxone CRO
trend · Escherichia coli
74 %
79 %
n = 105
trimethoprim TMP
trend · Escherichia coli lower UTI only
71 %
72 %
n = 105
69 %
75 %
n = 105
51 %
54 %
n = 105
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
13 %
n = 105
5 %
3 %
n = 105
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
5 %
n = 105

Most likely organisms for this profile

Escherichia coli
49 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
11 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.